Oral macrocyclic PCSK9-inhibiting peptide · Fact sheet
Enlicitide
Also known as Enlicitide decanoate · MK-0616 · Lipfendra
Enlicitide is the oral peptide in Lipfendra, approved to lower LDL cholesterol in adults with hypercholesterolemia. Its trials support cholesterol reduction; direct cardiovascular event prevention with enlicitide is a separate question.
What is Enlicitide?
Enlicitide inhibits PCSK9, helping preserve LDL receptors that remove cholesterol from blood. Its macrocyclic peptide structure differs from injectable antibody PCSK9 medicines.
Benefits people look for
Interest centers on LDL reduction and an oral approach to PCSK9 inhibition. Lower cholesterol and fewer cardiovascular events are related but distinct study endpoints.
What the evidence supports
- The controlled trials support substantial LDL lowering in the studied adult populations.
- Outcome evidence for other lipid medicines should not be presented as a completed enlicitide cardiovascular-outcomes trial.
All research areas
- LDL cholesterol
- Heterozygous familial hypercholesterolemia
- PCSK9 inhibition
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- Overall adverse-reaction frequency was similar to placebo in the broad hypercholesterolemia trial.
- Diarrhea and dizziness occurred more often in the familial-hypercholesterolemia trial.
- Pregnancy and breastfeeding involve specific uncertainties and precautions in the label.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Strong human evidence for approved usesThe label summarizes two 52-week randomized trials, including a large hypercholesterolemia study and a heterozygous familial hypercholesterolemia study. The approved endpoint is LDL reduction.
Selected research to read
Completed Phase 3 Merck-sponsored trial with LDL and safety outcomes; results posted.
Completed Phase 3 trial in heterozygous familial hypercholesterolemia; results posted.
FDA approval & research status
FDA approved Lipfendra on July 15, 2026, as an adjunct to diet and exercise to lower LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
Approved uses covered here
- Lipfendra: LDL reduction in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia
Lipfendra FDA approved in 2026
FDA approved Lipfendra on July 15, 2026, as an adjunct to diet and exercise to lower LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Direct cardiovascular-event outcomes with enlicitide
- Long-term experience beyond the pivotal studies
- Uncommon adverse effects in broader use
The takeaway
Enlicitide is an approved oral peptide with LDL-lowering evidence, not proof that every downstream cardiovascular claim is already established.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA: Lipfendra prescribing information
Product-specific approval, LDL results, and adverse effects.
- 2
- 3clinical trialsCORALreef Lipids registry
Completed Phase 3 Merck-sponsored trial with LDL and safety outcomes; results posted.
- 4clinical trialsCORALreef HeFH registry
Completed Phase 3 trial in heterozygous familial hypercholesterolemia; results posted.